A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis
Choose Your Experience
Over 500 Clients, Large & Small from Around the World, Trust Market Scope Data & Analysis
Latest Market Reports
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
- 269
Comprehensive Pages
- 8
Geographic and Economic Breakouts
- 5
Year Market Forecasts
- 52
Diseases Analyzed
2025 Cornea Products Market Report: Global Analysis for 2024 to 2030, December, 2025
The “2025 Cornea Products Market Report” delivers an in-depth analysis of the global cornea market, highlighting the latest advances in transplantation, crosslinking, and therapeutic devices aimed at restoring and preserving vision. The report estimates disease prevalence across six major corneal conditions and examines evolving treatment approaches, including cornea transplants, therapeutic lenses, phototherapeutic keratectomy (PTK), intrastromal ring segments, and corneal crosslinking.
It also explores the global ecosystem that supports cornea care—spanning organ donation systems, regulatory environments, and the pivotal roles of cornea specialists, eye banks, and nonprofit organizations.
This 2025 edition evaluates more than 70 products from over 50 companies, with forecasts for unit demand and revenue growth through 2030. It features analysis of emerging pipeline technologies yet to generate revenue and profiles 12 leading market participants shaping the future of cornea treatment.
Latest Industry News & Trends
8/28/2026
BreakingCataractEquipmentEuropeSurgical
Zeiss Introduces Cataract-Only Version of DORC Eva Nexus
German company Carl Zeiss Meditec introduced on Aug. 27 a dedicated cataract version of the DORC Eva Nexus surgical system. The original Eva Nexus, a dual-function cataract and vitrectomy machine, ...
8/28/2026
BreakingDealsGlaucomaPharmaRegulation
US FDA Accepts NDA for Glaucoma Drop from Nicox and Kowa, Sets PDUFA Date of April 30, 2027
France’s Nicox announced Aug. 27 that the US FDA had accepted the new drug application (NDA) for NCX 470 (bimatoprost grenod; also known as K-911) and set a Prescription Drug User Fee Act (PDUFA) t...
8/28/2026
BreakingClinical TrialDry EyePharma
Bausch + Lomb Advancing Dual-Action Dry Eye Drop, Ocular Surface Pain Candidate
Bausch + Lomb reported Aug. 24 that it would advance two of its topical ocular pipeline candidates based on clinical trial results. The company’s dual-action dry eye drop candidate—combining lifite...
8/28/2026
BreakingMyopiaStudy
Indigo Light Prevents Myopia in Animal Model, Researchers Find
Vision researchers have found that indigo light prevents myopia completely in a tree shrew model. Their findings were published Aug. 18, 2026, in Cell Reports Medicine. The study’s lead researchers...
8/28/2026
BreakingRegulation
Light-Filtering Lenses for Migraine from Avulux Gain US FDA De Novo Marketing Nod
Avulux announced Aug. 24 that its eyeglass lenses had gained US FDA de novo marketing authorization to decrease the impact of light sensitivity in patients ages 12 and older diagnosed with episodic...
8/28/2026
BreakingGlaucomaPharma
Santen Launches Rhopressa Glaucoma Drops in Japan
Santen announced Aug. 17 that it had launched Rhopressa (netarsudil ophthalmic solution) 0.02%, an eye drop targeting glaucoma and ocular hypertension, in Japan. The treatment gained marketing appr...
8/28/2026
BreakingPharmaRegulationRetina
Japan Grants Orphan Status to Alkeus’ Oral Gildeuretinol for Stargardt
Alkeus Pharmaceuticals announced Aug. 24 that Japan’s Ministry of Health, Labour, and Welfare had granted orphan drug status to gildeuretinol, its oral therapy candidate for Stargardt disease. In J...
8/20/2026
NewsletterRetina
Biosimilars, Longer-Acting Treatments Depress Exudative Retinal Pharma Revenue
Total manufacturers’ revenue from pharmaceuticals for exudative retinal diseases are on course to decline for the second year in a row—a first since the introduction of anti-VEGF therapy in 2004. M...
Provider Surveys & Interviews
Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Choose Your Own Adventure
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
Safe, Secure & On Any Device
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
Pre-Qualified Invitations
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
Better Data = Better Decisions
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
Download the Market Scope+ app to get started!
Market Scope Methodology
A Multi-Step Approach for Accurate & Timely Data
Proprietary data
- 20+ years of physician survey data
- Disease models
- Cultivated database of physicians, ASCs, and hospitals
- Insight from our team of in-house industry experts
Public data
- Attendance and participation at major, worldwide meetings
- Public health systems and registries
- Clinical study data
- Analysis of company-published financial reports
Join Market Scope Today
Register A Corporate Account
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.